ImageneBio, Inc. (IMA): M&A transaction — Ikena completes reverse merger with Inmagene, becomes ImageneBio; focuses on IMG-007 for atopic dermatitis

ImageneBio, Inc.

Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.
Reverse stock split 1-for-12; post-merger shares ~11.2M; pre-merger Inmagene holders get ~43.5% of combined co.
Only clinical asset: IMG-007 (anti-OX40 mAb) in Phase 2b ADAPTIVE trial for atopic dermatitis; non-OX40 assets divested.
CVR agreements provide contingent payments to legacy Ikena and Inmagene shareholders from future asset sales.
PIPE investors own ~21.5%; Hutchmed license has up to $92.5M in development/regulatory milestones plus royalties.

item 2.01 item 1.01 item 3.02 item 9.01 item 5.02 item 3.03 item 5.01 item 5.03 item 5.06 item 7.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ImageneBio, Inc.: Company ceased to be a shell company as a result of the Merger.

Change: shell status

Exact text from the filing

As a result of the Merger, the Company ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the closing of the Merger.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.99

ImageneBio, Inc. underwent a change of control involving Inmagene Biopharmaceuticals for Each Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock (closed 2025-07-25).

Action: change of control
Counterparty: Inmagene Biopharmaceuticals
Consideration: Each Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock
Closing: 2025-07-25

Exact text from the filing

Time were canceled and ceased to exist, and no consideration was delivered in exchange therefor, (b) each then-outstanding Inmagene Share was converted into the right to receive 0.0030510 shares of Ikena Common Stock, par value $0.001 per share (“ Ikena Common Stock ”) (such ratio, the “ Exchange Ratio ”) and (c) each then-outstanding option to purchase Inmagene

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-167089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.